Under terms of the agreement, Actavis can launch its generic version of Crestor 67 days prior to July 8, 2016, the expiration of pediatric exclusivity, at a fee of 39 percent of net sales to AstraZeneca...The FDA granted tentative approval to Actavis' ANDA on June 6, 2011

Deinove's contribution to the subsidiary are the results and intellectual property rights relating to research undertaken on antibiotics, as well as the transfer of the OSEO-ERDF-LR region funding already allocated – €700,000 (US$908,857...would entitle pSivida to a $25 million milestone payment from Alimera and 20 percent of net profits

Ltd., enabling Simcere Vaxtec to resume production of its influenza vaccine

In separate news, Astellas signed a deal to access the TSUBAME2.0 supercomputer at the Tokyo Institute of Technology to discover candidates for NTDs caused by dengue virus

InterMune expects to launch Esbriet in England and Wales by the end of June...The product would potentially be used as a companion diagnostic to hypoxia-targeted therapeutics based on Threshold's drug discovery platform...HX4 to determine a patient's tumor hypoxia profile

Cancer Research Technology, the commercial arm of Cancer Research UK, and the Institute of Cancer Research, London, said they were collaborating with Janssen Biotech Inc., a unit of New Brunswick, N.J.-based Johnson & Johnson, to discover a potential new multiple myeloma drug

Another $13 million to $15 million in equipment, integration service and testing will be provided by Agila...The resolution would authorize the board to effect a share consolidation at a rate of up to 10 to 1...The compounds are thought to have relevance for Parkinson's disease

According to Soligenix, the results showed that it is possible to produce vaccines capable of withstanding temperatures at least as high as 40 degrees C (104 degrees F) for at least six months, eliminating the standard cold chain production, distribution and storage logistics required for most vaccines...UCB has an option to exclusively license rights to selected protein targets discovered by FivePrime in the collaboration

The FDA stated that bleeding rates associated with new use of Pradaxa do not appear to be higher than those with new use of warfarin, which is consistent with observations from the pivotal RE-LY trial

Sosei licensed Japanese rights to the compound from BioAlliance, which markets the product as Loramyc/Oravig...The studies are designed to allow PCT to evaluate the applicability of SistemQC technology in stem cell characterization employing Sistemic's miRNA profiling system and analytical approaches to product miRNA panels

The news, he added, is positive for Epogen, so Amgen's shares (NASDAQ:AMGN) should rise as a result...Affymax already has proven its candidate noninferior to Epogen, and made publicly known that the price would be competitive, a relief to dialysis providers squeezed by the Centers for Medicare & Medicaid Services bundling rules. (See BioWorld Insight, Dec. 19, 2011, and BioWorld Today, Dec. 8, 2011.) Jim Birchenough, analyst with BMO Capital Markets, wrote in a research note at the time of the FDA

The news was hardly unexpected, as the product was nodded through by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) in January...In order to acquire something interesting, it's going to be very expensive, and some people are afraid they'll have to pay too high a price...Those and other questions are likely to get a further airing in Brussels Tuesday

Save for Wolbern Private Equity GmbH (WPE), no other partner who took part in the formal sale process made an offer, and WPE later withdrew its offer...Ark has been struggling to keep itself afloat since 2010, when the European Medicines Agency rejected gene therapy candidate Cerepro for use in glioma...Vanda said it intends to reassess its European regulatory strategy once those results become available

The news was hardly unexpected, as the product was nodded through by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) in January...In order to acquire something interesting, it's going to be very expensive, and some people are afraid they'll have to pay too high a price...Those and other questions are likely to get a further airing in Brussels Tuesday

In other news, law firm Bronstein, Gewirtz & Grossman LLC, of New York, said it is investigating claims on behalf of purchasers of Spectrum securities, after shares (NASDAQ:SPPI) fell as much as 38 percent on March 13 on news that the company slashed its revenue projections for colon cancer drug Fusilev (levoleucovorin

Astellas Pharma Inc., of Tokyo, said the European Commission approved expanded options for pre-treatment prior to use of Qutenza (8 percent capsaicin patch

Inc., of Whitehouse Station, N.J., and Luminex Corp., of Austin, Texas, signed a collaboration and license deal to develop a companion diagnostic device that will be evaluated to help screen patients for recruitment into Merck's clinical development program for MK-8931, an oral, beta amyloid precursor protein site cleaving enzyme inhibitor and Merck's lead candidate for Alzheimer's disease...Takeda Pharmaceutical Co., of Tokyo, and the Scripps Research Institute announced plans to expand their

That news "shocked the Street," according to Roth Capital Partners analyst Joseph Pantginis...Investors took the news hard, sending shares of Spectrum (NASDAQ:SPPI) falling $4.64, or 37.3 percent, to close Wednesday at $7.79

Clinigen Group plc, of Burton-on-Trent, UK, and Theravance Inc., of South San Francisco, entered an exclusive commercialization agreement in the European Union and certain other countries located in Europe for Vibativ (telavancin) in nosocomial pneumonia, including ventilator-associated pneumonia, known or suspected to be caused by methicillin-resistant Staphylococcus aureus, when other alternatives are not suitable...In other news, Elan said its Tysabri (natalizumab) restructuring transaction is